We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+6.08%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$42.8B
AUM Growth
+$3.35B
(+8.5%)
Cap. Flow
+$1.35B
Cap. Flow
% of AUM
3.15%
Top 10 Holdings %
Top 10 Hldgs %
14.82%
Holding
2,894
New
39
Increased
2,631
Reduced
168
Closed
44
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$21.8M |
| 2 |
Chevron
CVX
|
+$20.5M |
| 3 |
Berkshire Hathaway Class B
BRK.B
|
+$19.7M |
| 4 |
Incyte
INCY
|
+$17.8M |
| 5 |
ExxonMobil
XOM
|
+$16.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SE
Spectra Energy Corp Wi
SE
|
+$49.6M |
| 2 |
STJ
St Jude Medical
STJ
|
+$41.1M |
| 3 |
LLTC
Linear Technology Corp
LLTC
|
+$30.3M |
| 4 |
HAR
Harman International Industries
HAR
|
+$13.8M |
| 5 |
ENH
Endurance Specialty Holdings Ltd
ENH
|
+$10.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 16.2% |
| 2 | Technology | 15.06% |
| 3 | Healthcare | 13.05% |
| 4 | Industrials | 10.88% |
| 5 | Consumer Discretionary | 9.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1901
Novanta
NOVT
$5.08B
| $1.02M | ﹤0.01% |
38,347
+1,156
| +3% | +$28.2K |
|
1902
OFG Bancorp
OFG
$2.23B
| $1.02M | ﹤0.01% |
86,182
+24,309
| +39% | +$309K |
|
|
SBY
1903
DELISTED
Silver Bay Realty Trust Corp.
SBY
| $1.01M | ﹤0.01% |
47,268
+3,666
| +8% | +$69.8K |
|
1904
Upbound Group
UPBD
$1.13B
| $1.01M | ﹤0.01% |
114,361
+23,849
| +26% | +$217K |
|
1905
Globant
GLOB
$1.58B
| $1.01M | ﹤0.01% |
27,654
+848
| +3% | +$29.6K |
|
1906
Photronics
PLAB
$1.79B
| $1.01M | ﹤0.01% |
94,039
+3,488
| +4% | +$38.8K |
|
1907
AngioDynamics
ANGO
$611M
| $1M | ﹤0.01% |
57,932
+17,888
| +45% | +$299K |
|
1908
SiriusPoint
SPNT
$2.75B
| $1M | ﹤0.01% |
83,001
+3,404
| +4% | +$40.3K |
|
1909
CorVel
CRVL
$3.06B
| $1M | ﹤0.01% |
69,063
+14,478
| +27% | +$191K |
|
1910
Glaukos
GKOS
$9.83B
| $997K | ﹤0.01% |
19,434
+1,115
| +6% | +$48.6K |
|
|
HSII
1911
DELISTED
Heidrick & Struggles
HSII
| $993K | ﹤0.01% |
37,702
+9,808
| +35% | +$230K |
|
1912
Lattice Semiconductor
LSCC
$17.6B
| $993K | ﹤0.01% |
143,547
+7,871
| +6% | +$55.6K |
|
1913
Harmonic Inc
HLIT
$1.25B
| $992K | ﹤0.01% |
166,727
+44,151
| +36% | +$242K |
|
1914
Enterprise Financial Services Corp
EFSC
$2.4B
| $991K | ﹤0.01% |
23,378
+877
| +4% | +$37.2K |
|
|
SCLN
1915
DELISTED
Sciclone Pharmaceuticals Inc
SCLN
| $991K | ﹤0.01% |
101,172
+30,804
| +44% | +$308K |
|
1916
Manitowoc
MTW
$497M
| $989K | ﹤0.01% |
43,395
-2,075
| -5% | -$51.2K |
|
1917
Cohu
COHU
$2.26B
| $986K | ﹤0.01% |
53,436
+14,717
| +38% | +$223K |
|
1918
TTEC Holdings
TTEC
$121M
| $985K | ﹤0.01% |
33,291
+8,612
| +35% | +$260K |
|
1919
Amphastar Pharmaceuticals
AMPH
$879M
| $984K | ﹤0.01% |
67,838
+20,764
| +44% | +$326K |
|
1920
FormFactor
FORM
$8.28B
| $984K | ﹤0.01% |
83,061
+4,169
| +5% | +$48.3K |
|
|
VSI
1921
DELISTED
Vitamin Shoppe Inc.
VSI
| $984K | ﹤0.01% |
48,841
+12,895
| +36% | +$275K |
|
1922
National CineMedia
NCMI
$376M
| $982K | ﹤0.01% |
7,772
+234
| +3% | +$31.5K |
|
1923
Community Trust Bancorp
CTBI
$1.42B
| $981K | ﹤0.01% |
21,438
+547
| +3% | +$25.5K |
|
|
PGTI
1924
DELISTED
PGT, Inc.
PGTI
| $979K | ﹤0.01% |
91,080
+27,362
| +43% | +$302K |
|
|
SPPI
1925
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
| $979K | ﹤0.01% |
150,580
+40,984
| +37% | +$229K |
|
Similar funds
VAM
RhumbLine Advisers's Q1 2017 Portfolio in Review
As of Q1 2017, RhumbLine Advisers held 2,894 positions worth $42.8B, up 8.5% from $39.5B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
RhumbLine Advisers deployed $1.35B of net new capital in Q1 2017, opening 39 new positions and adding to 2,631 existing holdings. Its largest new stake was Bioverativ Inc. Common Stock: 197,812 shares worth $10.8M.
By sector, the portfolio is most concentrated in Financials at 16% of assets, down from 17% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was Biogen, an estimated $8.21M trimmed.
- RhumbLine Advisers's largest Q1 2017 buy was Bioverativ Inc. Common Stock: 197,812 shares worth $10.8M.
- RhumbLine Advisers added most to Abbott in Q1 2017, an estimated $21.8M increase.
- RhumbLine Advisers's biggest Q1 2017 reduction was Biogen, cutting an estimated $8.21M.
- RhumbLine Advisers fully exited Spectra Energy Corp Wi in Q1 2017, selling an estimated $49.6M.
- RhumbLine Advisers's ten largest holdings make up 15% of its $42.8B portfolio in Q1 2017.
- RhumbLine Advisers opened 39 new positions and closed 44 in Q1 2017.
- RhumbLine Advisers's portfolio value rose 8.5% quarter-over-quarter to $42.8B.
Based on RhumbLine Advisers's 13F filing for Q1 2017, filed 2 May 2017.